microRNA-497-5p-based screening identifies a novel synthetic lethal-type interaction via PKMYT1 and WEE1 in pleural mesothelioma
Related Experiment Video
Updated: Sep 15, 2025
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Nathanael Pruett1, Sierra Wilferd2, Anand Singh1
1Thoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
Diffuse pleural mesothelioma (DPM) is an incurable surface neoplasm governed by tumor suppressor losses with limited therapeutic options. Despite the advantages of leveraging the tumor suppressive activity of microRNA (miRNA/miR), clinical translation remains limited due to incomplete understanding of their context-specific gene targets. Here, we employed a biotinylated-miRNA pull-down approach to systematically identify direct targets of miR-497-5p, an miRNA markedly downregulated in DPM. Surprisingly, multiple identified targets were not predicted by in silico algorithms. Using patient samples, cell lines, murine xenograft models, and our localized nanoparticle miRNA delivery platform, we validated miR-497-5p anti-tumor mechanisms, which consisted of pro-apoptotic and anti-cell-cycle effects. Of multiple additional gene associations to DPM biology, we identified a synthetic lethal-type interaction whereby miR-497-5p co-inhibits PKMYT1 and WEE1 cell-cycle kinases (G2/M regulators). They were significantly overexpressed (poorly prognostic) in DPM, suggesting an efficacious treatment regimen to be explored. We demonstrate the utility of experimentally deriving the miR-497-5p targetome, explaining its pathophysiological role in DPM and why it is a rational therapeutic for further development.
Insights
MicroRNA-497-5p, downregulated in diffuse pleural mesothelioma (DPM), exhibits anti-tumor effects by targeting cell cycle kinases. This discovery offers a potential new therapeutic strategy for DPM treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Diffuse pleural mesothelioma (DPM) is an aggressive cancer with limited treatment options, often driven by tumor suppressor gene loss.
- MicroRNAs (miRNAs) show therapeutic potential but require precise target identification for clinical use.
- Understanding miRNA function in DPM is crucial for developing novel therapies.
Purpose of the Study:
- To systematically identify direct targets of the downregulated microRNA miR-497-5p in DPM.
- To elucidate the anti-tumor mechanisms and pathophysiological role of miR-497-5p in DPM.
- To explore miR-497-5p as a potential therapeutic agent for DPM.
Main Methods:
- Biotinylated-miRNA pull-down assay to identify direct miRNA targets.
- Validation using patient samples, cell lines, and murine xenograft models.
- Development and application of a localized nanoparticle miRNA delivery platform.
Main Results:
- Identified direct targets of miR-497-5p, some not predicted by computational methods.
- Validated pro-apoptotic and anti-cell-cycle effects of miR-497-5p in DPM models.
- Discovered a synthetic lethal interaction where miR-497-5p co-inhibits cell cycle kinases PKMYT1 and WEE1, which are overexpressed and associated with poor prognosis in DPM.
Conclusions:
- Experimentally derived miR-497-5p targetome provides insights into its role in DPM.
- miR-497-5p exhibits significant anti-tumor activity through apoptosis and cell cycle inhibition.
- Co-inhibition of PKMYT1 and WEE1 by miR-497-5p presents a promising therapeutic strategy for DPM.
